Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement
Cartesian Therapeutics is expanding Descartes-08 into myositis indications and pursuing an in vivo CAR-T approach. I rate RNAC stock as Buy. Click to read my full update.